- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT02038829
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD (GOLDEN 6)
A Dose-Range Finding Study of SUN-101 in Subjects With Moderate to Severe COPD: GOLDEN 6 (Glycopyrrolate for Obstructive Lung Disease Via Electronic Nebulizer)
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 2
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Florida
-
Clearwater, Florida, Estados Unidos, 33765
- Clinical Research of West Florida, Inc.
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28207
- American Health Research, Inc.
-
Raleigh, North Carolina, Estados Unidos, 27607
- North Carolina Clinical Research
-
-
Oregon
-
Medford, Oregon, Estados Unidos, 97504
- Clinical Research Institute of Southern Oregon, PC
-
-
South Carolina
-
Easley, South Carolina, Estados Unidos, 29640
- Palmetto Medical Research Associates, LLC
-
Greenville, South Carolina, Estados Unidos, 29615
- Upstate Pharmaceutical Research
-
Greenville, South Carolina, Estados Unidos, 29615
- Greenville Pharmaceutical Research, Inc.
-
Spartanburg, South Carolina, Estados Unidos, 29303
- Spartanburg Medical Research
-
Spartanburg, South Carolina, Estados Unidos, 29303
- S. Carolina
-
Union, South Carolina, Estados Unidos, 29379
- CU Pharmaceutical Research
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Male or female patients 40 to 65 years-old, inclusive.
- A clinical diagnosis of moderate to severe COPD according to the GOLD 2011 guidelines.
- Current smokers or ex-smokers with at least 10 pack year smoking history (eg, at least 1 pack/day for 10 years, or equivalent).
- Post bronchodilator (following inhalation of ipratropium bromide) FEV1 ≥ 40% and ≤ 70% of predicted normal during Screening.
- Post bronchodilator (following inhalation of ipratropium bromide) FEV1/FVC ratio ≤ 0.70 during Screening.
- Post bronchodilator (following inhalation of ipratropium bromide) improvement in FEV1 ≥ 12% and ≥ 100 mL during Screening.
- Ability to perform reproducible spirometry according to the American Thoracic Society (ATS) and European Respiratory Society (ERS) guidelines (2005).
Female of child bearing potential (only) must have a negative serum pregnancy test at Screening and be neither breastfeeding nor intending to become pregnant during study participation. Females of childbearing potential must be instructed to and agree to avoid pregnancy during the study. Female subjects of child bearing potential must use an adequate method of birth control from Screening until 30 days after receiving study drug and use contraception in addition to their partners using a barrier method. Acceptable forms of contraception are as follows:
- Abstinence
- Barrier methods: condoms, diaphragms, cervical caps; with a spermicide foam, gel, film, cream or suppository;
- Oral contraceptives
- Non hormone containing intrauterine methods: intrauterine devices or systems.
- Willing and able to remain at the study site for at least 24 hours at Day 7 of each Treatment Period.
- Willing and able to attend all study visits and adhere to all study assessments/procedures.
- Willing and able to provide written informed consent
Exclusion Criteria:
- Current evidence or recent history of any clinically significant and unstable disease (other than COPD) or abnormality in the opinion of the Investigator that would put the subject at risk or which would compromise the quality of the study data; including but not limited to cardiovascular disease, myocardial infarction, cardiac failure, uncontrolled hypertension, life threatening arrhythmias, uncontrolled diabetes, neurologic or neuromuscular disease, liver disease, gastrointestinal disease or electrolyte abnormalities.
- Current evidence or history of a clinically significant abnormality of cardiac rhythm and/or conduction including Holter monitoring prior to randomization.
- Primary diagnosis of asthma.
- History of malignancy of any organ system, treated or untreated within the past 5 years, with the exception of localized basal cell carcinoma of the skin.
- Recent history of COPD exacerbation requiring hospitalization or need for increased treatments for COPD within 6 weeks prior to Screening.
- Use of daily oxygen therapy > 10 hours per day.
- Use of systemic steroids within 3 months prior to Screening.
- Respiratory tract infection within 6 weeks prior to or during Screening.
- History of tuberculosis, bronchiectasis or other non-specific pulmonary disease.
- History of urinary retention or bladder neck obstruction type symptoms.
- History of narrow angle glaucoma.
- Prolonged QTcF interval (males > 450 msec and females >470 msec) during Screening, or history of long QT syndrome.
- Recent history (previous 12 months) of excessive use or abuse of alcohol or narcotic/illegal drugs.
- History of hypersensitivity or intolerance to aerosol medications, beta-2 agonists, or anticholinergics.
- Participation in another investigational drug study where drug was received within 30 days prior to Screening, or current participation in another investigational drug trial.
- Subject is a staff member of the clinical site or a relative of a clinical site staff member.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación cruzada
- Enmascaramiento: Cuadruplicar
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Comparador de placebos: Placebo
Placebo bid
|
Placebo
|
Experimental: SUN-101 3 mcg
SUN-101 3 mcg bid
|
SUN-101 3 mcg bid
|
Experimental: SUN-101 6.25 mcg
SUN-101 6.25 mcg bid
|
SUN-101 6.25 mcg bid
|
Experimental: SUN-101 12.5 mcg
SUN-101 12.5 mcg bid
|
SUN-101 12.5 mcg bid
|
Experimental: SUN-101 50 mcg
SUN-101 50 mcg bid
|
SUN-101 50 mcg bid
|
Comparador activo: Aclidinium 400 mcg
Aclidinium 400 mcg bid
|
Aclidinium 400 mcg bid
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Change From Baseline in Trough FEV1 at Treatment Visit Day 7 Compared to Placebo.
Periodo de tiempo: Baseline and Day 7
|
Spirometry was performed according to internationally accepted standards.
Trough FEV1 was defined as the average of the 2 spirometry values collected at 23 hours 15 minutes, and 23 hours 45 minutes post-morning dose on Day 7 of each Treatment Period.
The FEV1 values within 6 hours after the use of rescue medication were considered as missing.
Baseline was calculated as the mean of the FEV1 values at 45 minutes and 15 minutes prior to the morning dose at Day 1 of each Treatment Period
|
Baseline and Day 7
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Standardized Change From Baseline in FEV1 AUC(0-12hours)
Periodo de tiempo: Day 7
|
The standardized FEV1 AUC(0-12) on Day 7 was calculated using the trapezoidal rule from the changes in FEV1 from the baseline value (the mean of the two FEV1 values at 45 minutes and 15 minutes prior to morning dose at Day 1 of the respective Treatment Periods) and dividing by the actual length of the time interval).
|
Day 7
|
Number of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)
Periodo de tiempo: Over 7 days
|
A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.
|
Over 7 days
|
Percentage of Subjects With Treatment-emergent Adverse Events (Overall and by Treatment)
Periodo de tiempo: Over 7 days
|
A treatment emergent adverse event (TEAE) is any TEAE that occurred on or after the first dose of study medication, any SAE with a missing start date and a stop date on or after the first dose of study medication, or any TEAE with both a missing start and stop date.
|
Over 7 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: SUN101 Medical Director, MD, Sunovion
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Otros números de identificación del estudio
- SUN101-201
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre EPOC
-
PharmaxisTerminado
-
Liita Care ApSSuspendidoEPOC | Bronquitis copdDinamarca
-
Gala Therapeutics, Inc.Activo, no reclutandoBronquitis crónica | Bronquitis copdEstados Unidos